<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025843</url>
  </required_header>
  <id_info>
    <org_study_id>5478-001</org_study_id>
    <secondary_id>2009-016048-38</secondary_id>
    <nct_id>NCT01025843</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)</brief_title>
  <official_title>A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part introductory clinical trial with MK-5478. Part I will evaluate the safety,
      tolerability and pharmacokinetics and pharmacodynamics of MK-5478 in young, healthy males.
      Part II will evaluate the safety, tolerability and pharmacodynamic effects of MK-5478 in
      participants with hypertension. The primary hypothesis is that single oral doses of MK-5478
      are sufficiently safe and well tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2009</start_date>
  <completion_date type="Actual">May 1, 2010</completion_date>
  <primary_completion_date type="Actual">May 1, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days after administration of last dose of study drug (up to Day 52)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to an AE</measure>
    <time_frame>Up to 24 hours after administration of study drug</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, is also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC 0-infinity) of MK-5478 and Candesartan</measure>
    <time_frame>Pre-dose and up to 48 hours postdose</time_frame>
    <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure AUC 0-infinity of MK-5478 and Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aortic Augmentation Index (AIx) of MK-5478 and Candesartan</measure>
    <time_frame>Baseline and 1 to 3 hours postdose</time_frame>
    <description>Central blood pressure (CBP) parameters will be measured and used to derive the aortic augmentation index (AIx). The AIx quantifies the contribution of back-reflected outgoing systolic pressure waves to late-systolic central blood pressure, which increases with decreasing aortic compliance. AIx is measured by pulse wave analysis using the SphygmoCor System supplied by AtCor Medical. Results with a &gt; 5% decrease in AIx were planned for analysis; results with a &lt; 5% decrease in AIx were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-5478 and Candesartan</measure>
    <time_frame>Pre-dose and up to 48 hours postdose</time_frame>
    <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure the Cmax of MK-5478 and Candesartan</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg → 5 mg → 12 mg → Candesartan → Pbo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg → Candesartan → Pbo → 24 mg → 38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg → 5 mg → 12 mg → Pbo → Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg→Pbo → Candesartan → Pbo fed→38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg→Candesartan→Pbo→Candesartan fed→38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg → 8 mg → 18 mg → 2 mg fed → Pbo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan→8 mg→ 18 mg →2 mg fed→38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan→Pbo → 12 mg → 24 mg→38 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5478</intervention_name>
    <description>In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.</description>
    <arm_group_label>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Candesartan → Pbo</arm_group_label>
    <arm_group_label>1 mg → Candesartan → Pbo → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Pbo → Candesartan</arm_group_label>
    <arm_group_label>Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan</arm_group_label>
    <arm_group_label>2 mg→Pbo → Candesartan → Pbo fed→38 mg</arm_group_label>
    <arm_group_label>2 mg→Candesartan→Pbo→Candesartan fed→38 mg</arm_group_label>
    <arm_group_label>2 mg → 8 mg → 18 mg → 2 mg fed → Pbo</arm_group_label>
    <arm_group_label>Candesartan→8 mg→ 18 mg →2 mg fed→38 mg</arm_group_label>
    <arm_group_label>Candesartan→Pbo → 12 mg → 24 mg→38 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Candesartan cilexetil</intervention_name>
    <description>Single dose administration of candesartan, 32 mg oral tablet</description>
    <arm_group_label>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Candesartan → Pbo</arm_group_label>
    <arm_group_label>1 mg → Candesartan → Pbo → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Pbo → Candesartan</arm_group_label>
    <arm_group_label>Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan</arm_group_label>
    <arm_group_label>2 mg→Pbo → Candesartan → Pbo fed→38 mg</arm_group_label>
    <arm_group_label>2 mg→Candesartan→Pbo→Candesartan fed→38 mg</arm_group_label>
    <arm_group_label>2 mg → 8 mg → 18 mg → 2 mg fed → Pbo</arm_group_label>
    <arm_group_label>Candesartan→8 mg→ 18 mg →2 mg fed→38 mg</arm_group_label>
    <arm_group_label>Candesartan→Pbo → 12 mg → 24 mg→38 mg</arm_group_label>
    <other_name>Atacand/Amias</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Pbo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Candesartan → Pbo</arm_group_label>
    <arm_group_label>1 mg → Candesartan → Pbo → 24 mg → 38 mg</arm_group_label>
    <arm_group_label>1 mg → 5 mg → 12 mg → Pbo → Candesartan</arm_group_label>
    <arm_group_label>Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan</arm_group_label>
    <arm_group_label>2 mg→Pbo → Candesartan → Pbo fed→38 mg</arm_group_label>
    <arm_group_label>2 mg→Candesartan→Pbo→Candesartan fed→38 mg</arm_group_label>
    <arm_group_label>2 mg → 8 mg → 18 mg → 2 mg fed → Pbo</arm_group_label>
    <arm_group_label>Candesartan→8 mg→ 18 mg →2 mg fed→38 mg</arm_group_label>
    <arm_group_label>Candesartan→Pbo → 12 mg → 24 mg→38 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part I:

          -  Is a male between 18 to 50 years of age

          -  Is in good health

          -  Is a non-smoker

        Part II:

          -  Is male of non-child bearing potential between 18 and 50 years of age

          -  Has hypertension (high blood pressure)

        Exclusion Criteria:

        Part I and Part II:

          -  Has a history of stroke, seizures or major neurological disorder

          -  Has a history of cancer

          -  Has a history of any cardiovascular disease

          -  Is unable to refrain from the use of any prescription or non-prescription drugs

          -  Consumes excessive amounts of alcohol or caffeine

          -  Has had major surgery, donated blood or participated in another investigational study
             in the past 4 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>January 28, 2016</results_first_submitted>
  <results_first_submitted_qc>January 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2016</results_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=5478-001&amp;kw=5478-001&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A Part II of this study was planned. However, since the efficacy criteria for advancing to Part II were not met in Part I, this study was considered completed with the completion of Part I. Therefore participants were not recruited for Part II.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</title>
          <description>Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P2">
          <title>1 mg → 5 mg → 12 mg → Candesartan → Pbo</title>
          <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P3">
          <title>1 mg → Candesartan → Pbo → 24 mg → 38 mg</title>
          <description>1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK- 5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P4">
          <title>1 mg → 5 mg → 12 mg → Pbo → Candesartan</title>
          <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P5">
          <title>Pbo → 8 mg→ 18 mg → 2 mg Fed → Candesartan</title>
          <description>Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P6">
          <title>2 mg→Pbo → Candesartan → Pbo Fed → 38 mg</title>
          <description>2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P7">
          <title>2 mg→Candesartan→ Pbo → Candesartan Fed → 38 mg</title>
          <description>2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P8">
          <title>2 mg → 8 mg → 18 mg → 2 mg Fed → Pbo</title>
          <description>2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P9">
          <title>Candesartan→8 mg→ 18 mg → 2 mg Fed → 38 mg</title>
          <description>Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="P10">
          <title>Candesartan → Pbo → 12 mg → 24 mg → 38 mg</title>
          <description>Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK- 5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Pbo → 5 mg → Candesartan → 24 mg → 38 mg</title>
          <description>Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods</description>
        </group>
        <group group_id="B2">
          <title>1 mg → 5 mg → 12 mg → Candesartan → Pbo</title>
          <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B3">
          <title>1 mg → Candesartan → Pbo → 24 mg → 38 mg</title>
          <description>1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK- 5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B4">
          <title>1 mg → 5 mg → 12 mg → Pbo → Candesartan</title>
          <description>1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B5">
          <title>Pbo → 8 mg→ 18 mg → 2 mg Fed → Candesartan</title>
          <description>Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B6">
          <title>2 mg→Pbo → Candesartan → Pbo Fed → 38 mg</title>
          <description>2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B7">
          <title>2 mg→Candesartan→ Pbo → Candesartan Fed → 38 mg</title>
          <description>2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B8">
          <title>2 mg → 8 mg → 18 mg → 2 mg Fed → Pbo</title>
          <description>2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B9">
          <title>Candesartan→8 mg→ 18 mg → 2 mg Fed → 38 mg</title>
          <description>Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.</description>
        </group>
        <group group_id="B10">
          <title>Candesartan → Pbo → 12 mg → 24 mg → 38 mg</title>
          <description>Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK- 5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="2"/>
            <count group_id="B11" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="46" upper_limit="47"/>
                    <measurement group_id="B2" value="38.5" lower_limit="29" upper_limit="48"/>
                    <measurement group_id="B3" value="46.0" lower_limit="45" upper_limit="47"/>
                    <measurement group_id="B4" value="35.0" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="B5" value="37.5" lower_limit="36" upper_limit="39"/>
                    <measurement group_id="B6" value="44.5" lower_limit="40" upper_limit="49"/>
                    <measurement group_id="B7" value="48.0" lower_limit="46" upper_limit="50"/>
                    <measurement group_id="B8" value="46.5" lower_limit="44" upper_limit="49"/>
                    <measurement group_id="B9" value="45.0" lower_limit="42" upper_limit="48"/>
                    <measurement group_id="B10" value="39.0" lower_limit="38" upper_limit="40"/>
                    <measurement group_id="B11" value="45.5" lower_limit="21" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Adverse Events (AEs)</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
        <time_frame>Up to 14 days after administration of last dose of study drug (up to Day 52)</time_frame>
        <population>All participants who received at least one dose of the investigational drug, according to the treatment(s) they actually received; according to study drug taken at time of the event and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5478 1 mg</title>
            <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O2">
            <title>MK-5478 2 mg</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O3">
            <title>MK-5478 5 mg</title>
            <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O4">
            <title>MK-5478 8 mg</title>
            <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O5">
            <title>MK-5478 12 mg</title>
            <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O6">
            <title>MK-5478 18 mg</title>
            <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O7">
            <title>MK-5478 24 mg</title>
            <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O8">
            <title>MK-5478 38 mg</title>
            <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O9">
            <title>MK-5478 2 mg - Fed</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Candesartan 32 mg</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O11">
            <title>Candesartan 32 mg - Fed</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O12">
            <title>Candesartan Placebo</title>
            <description>A single dose of Candesartan placebo in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O13">
            <title>MK-5478 Placebo</title>
            <description>A single dose of MK-5478 Placebo in capsule form was orally administered during a treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events (AEs)</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
          <population>All participants who received at least one dose of the investigational drug, according to the treatment(s) they actually received; according to study drug taken at time of the event and not by randomly assigned sequence.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Treatment Due to an AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
        <time_frame>Up to 24 hours after administration of study drug</time_frame>
        <population>All participants who received at least one dose of the investigational drug, according to the treatment(s) they actually received; according to study drug taken at time of the event and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5478 1 mg</title>
            <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O2">
            <title>MK-5478 2 mg</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O3">
            <title>MK-5478 5 mg</title>
            <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O4">
            <title>MK-5478 8 mg</title>
            <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O5">
            <title>MK-5478 12 mg</title>
            <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O6">
            <title>MK-5478 18 mg</title>
            <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O7">
            <title>MK-5478 24 mg</title>
            <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O8">
            <title>MK-5478 38 mg</title>
            <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O9">
            <title>MK-5478 2 mg - Fed</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Candesartan 32 mg</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O11">
            <title>Candesartan 32 mg - Fed</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O12">
            <title>Candesartan Placebo</title>
            <description>A single dose of Candesartan placebo in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O13">
            <title>MK-5478 Placebo</title>
            <description>A single dose of MK-5478 Placebo in capsule form was orally administered during a treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Treatment Due to an AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR’s product, is also an AE.</description>
          <population>All participants who received at least one dose of the investigational drug, according to the treatment(s) they actually received; according to study drug taken at time of the event and not by randomly assigned sequence.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC 0-infinity) of MK-5478 and Candesartan</title>
        <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure AUC 0-infinity of MK-5478 and Candesartan</description>
        <time_frame>Pre-dose and up to 48 hours postdose</time_frame>
        <population>In order to keep the study blinded, the scheduled number of treated participants rather than the actual number of treated participants were analyzed; according to the scheduled study drug and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5478 1 mg</title>
            <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O2">
            <title>MK-5478 2 mg</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O3">
            <title>MK-5478 5 mg</title>
            <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O4">
            <title>MK-5478 8 mg</title>
            <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O5">
            <title>MK-5478 12 mg</title>
            <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O6">
            <title>MK-5478 18 mg</title>
            <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O7">
            <title>MK-5478 24 mg</title>
            <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O8">
            <title>MK-5478 38 mg</title>
            <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O9">
            <title>MK-5478 2 mg - Fed</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Candesartan 32 mg</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O11">
            <title>Candesartan 32 mg - Fed</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC 0-infinity) of MK-5478 and Candesartan</title>
          <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure AUC 0-infinity of MK-5478 and Candesartan</description>
          <population>In order to keep the study blinded, the scheduled number of treated participants rather than the actual number of treated participants were analyzed; according to the scheduled study drug and not by randomly assigned sequence.</population>
          <units>umol.hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" spread="0.141"/>
                    <measurement group_id="O2" value="0.494" spread="0.202"/>
                    <measurement group_id="O3" value="1.87" spread="0.538"/>
                    <measurement group_id="O4" value="1.80" spread="0.436"/>
                    <measurement group_id="O5" value="1.36" spread="0.448"/>
                    <measurement group_id="O6" value="2.23" spread="0.582"/>
                    <measurement group_id="O7" value="3.15" spread="1.55"/>
                    <measurement group_id="O8" value="4.50" spread="0.857"/>
                    <measurement group_id="O9" value="0.504" spread="0.07"/>
                    <measurement group_id="O10" value="5.89" spread="1.38"/>
                    <measurement group_id="O11" value="4.46" spread="0.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aortic Augmentation Index (AIx) of MK-5478 and Candesartan</title>
        <description>Central blood pressure (CBP) parameters will be measured and used to derive the aortic augmentation index (AIx). The AIx quantifies the contribution of back-reflected outgoing systolic pressure waves to late-systolic central blood pressure, which increases with decreasing aortic compliance. AIx is measured by pulse wave analysis using the SphygmoCor System supplied by AtCor Medical. Results with a &gt; 5% decrease in AIx were planned for analysis; results with a &lt; 5% decrease in AIx were not analysed.</description>
        <time_frame>Baseline and 1 to 3 hours postdose</time_frame>
        <population>Results were not analyzed because none showed a &gt; 5% decrease in AIx.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5478 1 mg</title>
            <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O2">
            <title>MK-5478 2 mg</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O3">
            <title>MK-5478 5 mg</title>
            <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O4">
            <title>MK-5478 8 mg</title>
            <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O5">
            <title>MK-5478 12 mg</title>
            <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O6">
            <title>MK-5478 18 mg</title>
            <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O7">
            <title>MK-5478 24 mg</title>
            <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O8">
            <title>MK-5478 38 mg</title>
            <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O9">
            <title>MK-5478 2 mg - Fed</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Candesartan 32 mg</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O11">
            <title>Candesartan 32 mg - Fed</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Augmentation Index (AIx) of MK-5478 and Candesartan</title>
          <description>Central blood pressure (CBP) parameters will be measured and used to derive the aortic augmentation index (AIx). The AIx quantifies the contribution of back-reflected outgoing systolic pressure waves to late-systolic central blood pressure, which increases with decreasing aortic compliance. AIx is measured by pulse wave analysis using the SphygmoCor System supplied by AtCor Medical. Results with a &gt; 5% decrease in AIx were planned for analysis; results with a &lt; 5% decrease in AIx were not analysed.</description>
          <population>Results were not analyzed because none showed a &gt; 5% decrease in AIx.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of MK-5478 and Candesartan</title>
        <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure the Cmax of MK-5478 and Candesartan</description>
        <time_frame>Pre-dose and up to 48 hours postdose</time_frame>
        <population>In order to keep the study blinded, the scheduled number of treated participants rather than the actual number of treated participants were analyzed; according to the scheduled study drug and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-5478 1 mg</title>
            <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O2">
            <title>MK-5478 2 mg</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O3">
            <title>MK-5478 5 mg</title>
            <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O4">
            <title>MK-5478 8 mg</title>
            <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O5">
            <title>MK-5478 12 mg</title>
            <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O6">
            <title>MK-5478 18 mg</title>
            <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O7">
            <title>MK-5478 24 mg</title>
            <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O8">
            <title>MK-5478 38 mg</title>
            <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
          </group>
          <group group_id="O9">
            <title>MK-5478 2 mg - Fed</title>
            <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
          <group group_id="O10">
            <title>Candesartan 32 mg</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
          </group>
          <group group_id="O11">
            <title>Candesartan 32 mg - Fed</title>
            <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of MK-5478 and Candesartan</title>
          <description>Blood was collected at the following time points: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, and 48 hours post-dose in order to measure the Cmax of MK-5478 and Candesartan</description>
          <population>In order to keep the study blinded, the scheduled number of treated participants rather than the actual number of treated participants were analyzed; according to the scheduled study drug and not by randomly assigned sequence.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0291" spread="0.012"/>
                    <measurement group_id="O2" value="0.0573" spread="0.0206"/>
                    <measurement group_id="O3" value="0.254" spread="0.0588"/>
                    <measurement group_id="O4" value="0.227" spread="0.0630"/>
                    <measurement group_id="O5" value="0.120" spread="0.0332"/>
                    <measurement group_id="O6" value="0.245" spread="0.0634"/>
                    <measurement group_id="O7" value="0.321" spread="0.206"/>
                    <measurement group_id="O8" value="0.532" spread="0.154"/>
                    <measurement group_id="O9" value="0.0553" spread="0.00891"/>
                    <measurement group_id="O10" value="0.476" spread="0.194"/>
                    <measurement group_id="O11" value="0.451" spread="0.0641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days after administration of last dose of study drug (up to Day 52)</time_frame>
      <desc>All participants who received at least one dose of the investigational drug, according to the treatment(s) they actually received; according to study drug taken at time of the event and not by randomly assigned sequence.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-5478 1 mg</title>
          <description>A single dose of 1 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E2">
          <title>MK-5478 2 mg</title>
          <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E3">
          <title>MK-5478 5 mg</title>
          <description>A single dose of 5 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E4">
          <title>MK-5478 8 mg</title>
          <description>.A single dose of 8 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E5">
          <title>MK-5478 12 mg</title>
          <description>A single dose of 12 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E6">
          <title>MK-5478 18 mg</title>
          <description>A single dose of 18 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E7">
          <title>MK-5478 24 mg</title>
          <description>A single dose of 24 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E8">
          <title>MK-5478 38 mg</title>
          <description>A single dose of 38 mg MK-5478 in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E9">
          <title>MK-5478 2 mg - Fed</title>
          <description>A single dose of 2 mg MK-5478 in capsule form was orally administered during a treatment period, preceded by a high fat breakfast</description>
        </group>
        <group group_id="E10">
          <title>MK-5478 Placebo</title>
          <description>A single dose of MK-5478 Placebo in capsule form was orally administered during a treatment period</description>
        </group>
        <group group_id="E11">
          <title>Candesartan 32 mg</title>
          <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period</description>
        </group>
        <group group_id="E12">
          <title>Candesartan 32 mg - Fed</title>
          <description>A single dose of 32 mg Candesartan in tablet form was orally administered during a treatment period, preceded by a high fat breakfast</description>
        </group>
        <group group_id="E13">
          <title>Candesartan Placebo</title>
          <description>A single dose of Candesartan placebo in tablet form was orally administered during a treatment period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

